全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Determination of Ranitidine in Human Plasma by SPE and ESI-LC-MS/MS for Use in Bioequivalence Studies

DOI: 10.1155/2013/484592

Full-Text   Cite this paper   Add to My Lib

Abstract:

A method for determining ranitidine in human plasma by ESI-LC-MS/MS was validated, using propranolol as internal standard. The extraction method used was solid phase extraction (SPE). Chromatographic separation was performed in a Chromolith C18 (50?mm × 4.6?mm i.d.) analytical column, which provided good separation of ranitidine and propranolol peaks with an analysis time of 2.5 minutes. Extraction yields of 94.4% for ranitidine and 89.4% for the internal standard were obtained. The lower limit of quantification (LLOQ) was 3.00?ng/mL, and limit of detection (LOD) was 0.05?ng/mL, with linearity ranging from 3.00 to 500?ng/mL. The results, thus, showed that this method is suitable for application in bioequivalence studies of ranitidine in human plasma. 1. Introduction The chemical structure of ranitidine hydrochloride (Figure 1) consists of a five-membered furan heterocyclic ring and a nitroethenodiaminic group. The molecular mass of ranitidine hydrochloride is 350.9 daltons (g/mol), and its molecular formula is C13H22N4O3SHCl corresponding to hydrochloride N[2-[[[5-[(dimethylamine)methyl)-2-furan]methyl]thio]ethyl]-N′-methyl-nitro2-1,1-ethenodiamine. Ranitidine hydrochloride appears as a crystalline powder, practically odorless and white to light yellow. It is very soluble in water, somewhat soluble in alcohol, and slightly soluble in chloroform. Furthermore, it should be stored in hermetically sealed containers and protected from light [1]. Figure 1: Chemical structure of ranitidine hydrochloride. Ranitidine is widely used in the treatment of gastric pathologies, has a chemical structure that partially resembles histamine, and acts primarily as a competitive histamine inhibitor through the H2 receptors [2, 3]. Since around two thousand analyses are conducted before bioequivalence studies can be concluded, the search for quick and simple methods to determine drugs in biological matrices has been intense. Thus, several methods for determining ranitidine in human plasma have been reported. Zendelovska and Stafilov [4] developed a method for determining ranitidine and cimetidine in human plasma using HPLC with a diode array detector. In this study, the analysis time was 9 minutes, with a 50.0?ng/mL limit of detection for ranitidine. Famotidine was used as internal standard. In another study using the same detector, an analysis time of 6.5 minutes was obtained in a C18 column (300?mm 4.6?mm id, 5?μm), with a limit of quantification of 20.0?ng/mL [5]. Methods for analyzing ranitidine in plasma by LC-MS/MS have been reported in some studies [6–8]. The limits

References

[1]  United States Pharmacopeial Convention, U.S. Pharmacopeia & National Formulary, National Publishing, Philadelphia, Pa, USA, 24th edition, 2000.
[2]  M. A. Rocha Júnior, “Histamina e Anti-histamínicos,” in Farmacologia, P. Silva, Ed., p. 54, Guanabara Koogan, Rio de Janeiro, Brazil, 5th edition, 1998.
[3]  J. Dawson, D. A. Richards, and R. Stables, “Ranitidine—pharmacology and clinical use,” Journal of Clinical and Hospital Pharmacy, vol. 8, no. 1, pp. 1–13, 1983.
[4]  D. Zendelovska and T. Stafilov, “Development of an HPLC method for the determination of ranitidine and cimetidine in human plasma following SPE,” Journal of Pharmaceutical and Biomedical Analysis, vol. 33, no. 2, pp. 165–173, 2003.
[5]  T. G. Do Nascimento, E. De Jesus Oliveira, and R. O. Macêdo, “Simultaneous determination of ranitidine and metronidazole in human plasma using high performance liquid chromatography with diode array detection,” Journal of Pharmaceutical and Biomedical Analysis, vol. 37, no. 4, pp. 777–783, 2005.
[6]  L. Wang, L.-M. Zhao, Y.-T. Sun, and J.-K. Gu, “Rapid determination of ranitidine in human plasma by liquid chromatography-tandem mass spectrometry and its application to a clinical pharmacokinetic study,” Chemical Research in Chinese Universities, vol. 26, no. 6, pp. 910–914, 2010.
[7]  Y. Zhang, N. Mehrotra, N. R. Budha, M. L. Christensen, and B. Meibohm, “A tandem mass spectrometry assay for the simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and theophylline in small volume pediatric plasma specimens,” Clinica Chimica Acta, vol. 398, no. 1-2, pp. 105–112, 2008.
[8]  X. Sun, Y. Tian, Z. Zhang, and Y. Chen, “A single LC-tandem mass spectrometry method for the simultaneous determination of four H2 antagonists in human plasma,” Journal of Chromatography B, vol. 877, no. 31, pp. 3953–3959, 2009.
[9]  A. Schellen, B. Ooms, D. Van De Lagemaat, R. Vreeken, and W. D. Van Dongen, “Generic solid phase extraction-liquid chromatography-tandem mass spectrometry method for fast determination of drugs in biological fluids,” Journal of Chromatography B, vol. 788, no. 2, pp. 251–259, 2003.
[10]  H. Kataoka, H. L. Lord, and J. Pawliszyn, “Automated in-tube solid-phase microextraction-liquid chromatography-electrospray ionization mass spectrometry for the determination of ranitidine,” Journal of Chromatography B, vol. 731, no. 2, pp. 353–359, 1999.
[11]  Y. Q. Xia, R. Bakhtiar, and R. B. Franklin, “Automated online dual-column extraction coupled with teicoplanin stationary phase for simultaneous determination of (R)- and (S)-propranolol in rat plasma using liquid chromatography-tandem mass spectrometry,” Journal of Chromatography B, vol. 788, no. 2, pp. 317–329, 2003.
[12]  M. A. Campanero, A. Lopez-Ocariz, E. García-Quetglás, B. Sádaba, and A. De La Maza, “Rapid determination of ranitidine in human plasma by high-performance liquid chromatography,” Chromatographia, vol. 47, no. 7-8, pp. 391–395, 1998.
[13]  G. Mullersman and H. Derendorf, “Rapid analysis of ranitidine in biological fluids and determination of its erythrocyte partitioning,” Journal of Chromatography, vol. 381, no. 2, pp. 385–391, 1986.
[14]  K. S. Reynolds, M. H. Song, W. D. Heizer, C. B. Burns, D. A. Sica, and K. L. R. Brouwer, “Effect of pancreatico-biliary secretions and GI transit time on the absorption and pharmacokinetic profile of ranitidine in humans,” Pharmaceutical Research, vol. 15, no. 8, pp. 1281–1285, 1998.
[15]  R. Miller, “Pharmacokinetics and bioavailability of ranitidine in humans,” Journal of Pharmaceutical Sciences, vol. 73, no. 10, pp. 1376–1379, 1984.
[16]  P. Schaiquevich, A. Niselman, and M. Rubio, “Comparison of two compartmental models for describing ranitidine's plasmatic profiles,” Pharmacological Research, vol. 45, no. 5, pp. 399–405, 2002.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133